Literature DB >> 21110118

Specific subtyping of influenza A virus using a recombinant hemagglutinin protein expressed in baculovirus.

Shahla Shahsavandi1, Ali-Hatef Salmanian, Seyed Ali Ghorashi, Shahin Masoudi, Fatemeh Fotouhi, Mohammad Majid Ebrahimi.   

Abstract

Influenza A viruses are subtyped according to antigen characterization of hemagglutinin (HA) and neuraminidase surface glycoproteins. The hemagglutination inhibition (HI) assay using reference antiserum is currently applied to serologic screening of subtype-specific antibodies in sera. The reference antiserum is made by injecting chickens with live or inactivated whole virus preparations. Nonspecific inhibitors of antisera prepared by the conventional method may affect the specificity of HI assay. In this study, highly pure recombinant proteins generated using baculovirus expression vector system based on full-length of HA (HAF) and antigenic region of HA(1) genes of H9 subtype, and also inactivated whole virus were used to immunization of chickens. Measurable antibody titers were present for treated birds after 3 weeks and generally increased after each boost. The performance of the prepared antisera was evaluated by testing a panel of known standard strains of influenza virus representing five HA subtypes. Relative to the conventional method using whole virus immunization and recombinant HAF protein, the antiserum prepared by recombinant HA(1) had a specificity of 100% for all tested subtypes. The antiserum prepared by expression of HA1 protein in baculovirus has the potential for rapid and specific HA subtyping of influenza viruses without producing antibodies specific to other viral proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110118     DOI: 10.1007/s11033-010-0434-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  24 in total

Review 1.  The role of the antibody response in influenza virus infection.

Authors:  W Gerhard
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

Authors:  Taff Jones; Francine Allard; Sonya L Cyr; Steven P Tran; Martin Plante; Joelle Gauthier; Nathalie Bellerose; George H Lowell; David S Burt
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

3.  Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong?

Authors:  Y Guan; K F Shortridge; S Krauss; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  Receptor specificity of influenza viruses from birds and mammals: new data on involvement of the inner fragments of the carbohydrate chain.

Authors:  Alexandra Gambaryan; Svetlana Yamnikova; Dmitryi Lvov; Alexander Tuzikov; Alexander Chinarev; Galina Pazynina; Robert Webster; Mikhail Matrosovich; Nicolai Bovin
Journal:  Virology       Date:  2005-04-10       Impact factor: 3.616

5.  H5N1 influenza: a protean pandemic threat.

Authors:  Y Guan; L L M Poon; C Y Cheung; T M Ellis; W Lim; A S Lipatov; K H Chan; K M Sturm-Ramirez; C L Cheung; Y H C Leung; K Y Yuen; R G Webster; J S M Peiris
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

6.  Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants.

Authors:  P N Graves; J L Schulman; J F Young; P Palese
Journal:  Virology       Date:  1983-04-15       Impact factor: 3.616

7.  Development of a multiplex real-time PCR assay using SYBR Green 1 chemistry for simultaneous detection and subtyping of H9N2 influenza virus type A.

Authors:  Wee Theng Ong; Abdul Rahman Omar; Aini Ideris; Sharifah Syed Hassan
Journal:  J Virol Methods       Date:  2007-05-23       Impact factor: 2.014

8.  Application of real-time RT-PCR for the quantitation and competitive replication study of H5 and H7 subtype avian influenza virus.

Authors:  Chang-Won Lee; David L Suarez
Journal:  J Virol Methods       Date:  2004-08       Impact factor: 2.014

9.  Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses.

Authors:  F X Bosch; W Garten; H D Klenk; R Rott
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

10.  Antigenic structure of the hemagglutinin of H9N2 influenza viruses.

Authors:  Masatoshi Okamatsu; Yoshihiro Sakoda; Noriko Kishida; Norikazu Isoda; Hiroshi Kida
Journal:  Arch Virol       Date:  2008-11-07       Impact factor: 2.574

View more
  5 in total

1.  Expression, purification and characterization of low-glycosylation influenza neuraminidase in α-1,6-mannosyltransferase defective Pichia pastoris.

Authors:  Yi-Li Yang; Shao-Hong Chang; Xin Gong; Jun Wu; Bo Liu
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

2.  Antiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection.

Authors:  Ye Liu; Hong Chen; Yajiao Sun; Fuhui Chen
Journal:  Mol Biol Rep       Date:  2011-05-21       Impact factor: 2.316

3.  Development of neuraminidase subtype-specific reference antisera by recombinant protein expressed in baculovirus.

Authors:  Kyu-Jun Lee; Jun-Gu Choi; Hyun-Mi Kang; Kwang-Il Kim; Choi-Kyu Park; Youn-Jeong Lee
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 4.  Pseudotype-based neutralization assays for influenza: a systematic analysis.

Authors:  George William Carnell; Francesca Ferrara; Keith Grehan; Craig Peter Thompson; Nigel James Temperton
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

5.  The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays.

Authors:  Francesca Ferrara; Eleonora Molesti; Simon Scott; Giovanni Cattoli; Nigel Temperton
Journal:  Pathogens       Date:  2017-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.